Health News

Chelsea Therapeutics International, Ltd. announced confirmation by the U.S. Food and Drug Administration (FDA) that its proposed Phase II protocol for CH-4051 in rheumatoid arthritis has been approved by the agency.

Read more

Filed under: Pharmacy News
Tags: Arthritis, Drug, Pharmacy

Related posts

• VIMOVO delayed-release tablets receive FDA approval (0)
  AstraZeneca and POZEN Inc. today announced the U.S. Food and Drug Administration has approved VIMOVO (naproxen and esomeprazole magnesium) delayed-release tablets for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers. Read more [tags] Pharmacy [...]
  
  
• Update on Phase II clinical study of CH-4051 in rheumatoid arthritis (0)
  Chelsea Therapeutics International, Ltd. announced that during a teleconference yesterday, the U.S. Food and Drug Administration requested that the company delay the initiation of its proposed Phase II clinical study of CH-4051 in rheumatoid arthritis and indicated that the agency is requesting additional detail from the preclinical studies previously submitted as part of the company's [...]
  
  
• U.S. Food And Drug Administration Accepts Supplemental Biologics License Application For Subcutaneous Formulation Of ORENCIA® (abatacept) (0)
  Bristol-Myers Squibb Company (NYSE: BMY) announced that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental Biologics License Application (sBLA) for the subcutaneous formulation of ORENCIA® (abatacept), a treatment for adult patients with moderate to severe rheumatoid arthritis (RA) administered through an injection into the skin... Read more [tags] Pharmacy News [/tags]
  
  
• Trubion Pharmaceuticals, Inc. Announces Initiation Of Phase 1 Study Of SBI-087 For The Treatment Of Systemic Lupus Erythematosus (SLE) (0)
  Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) announced that its collaboration partner Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), has initiated a Phase 1 clinical trial of SBI-087, Trubion's next generation CD20 drug candidate, for the treatment of systemic lupus erythematosus (SLE). Based on Trubion's Small Modular ImmunoPharmaceutical (SMIP(TM)) technology, SBI-087 is also being [...]
  
  
• Transition commences dosing in TT-301 Phase 1 clinical study for rheumatoid arthritis, ICH, TBI (0)
  Transition Therapeutics Inc. announced today that the first patient has been dosed with drug candidate TT-301 in a Phase 1 clinical study. TT-301 is a small molecule compound that has demonstrated efficacy in preclinical models of rheumatoid arthritis, intracerebral haemorrhage and traumatic brain injury. Read more [tags] Pharmacy News [/tags]